JA
ADMS

JOYN Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

JOYN Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-36
Closed -$1K – 1941
2018
Q2 		$1K Sell
36
-511
-93% -$14.1K ﹤0.01% 1699
2018
Q1 		$13K Buy
+547
New +$17.2K ﹤0.01% 743

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

JOYN Advisors's ADMS Position: Q3 2018 in Review

JOYN Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 36 shares — an estimated $1K sold.

JOYN Advisors first reported a position in ADMS in Q1 2018 and held it in 2 quarters. The position peaked at $13K in Q1 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • JOYN Advisors reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • JOYN Advisors sold 36 Adamas Pharmaceuticals shares in Q3 2018, an estimated $1K.
  • JOYN Advisors first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • JOYN Advisors's Adamas Pharmaceuticals position peaked at $13K in Q1 2018.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on JOYN Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.